So you typed “what is DLP1” and got a mix of cryptic research papers and forum posts — I’ve been there. Here’s the plain-talk answer: DLP1 (dipeptidyl peptidase-like protein 1, or sometimes referred to as DPP1 in early literature) is a lesser-known peptide that shares structural similarities with GLP-1 but acts through a distinct pathway. While GLP-1 has dominated headlines for weight loss and diabetes, DLP1 is quietly gaining attention for its potential role in fine-tuning insulin release and modulating gut-brain signaling, without the nausea that often accompanies traditional GLP-1 therapies. In clinical pipelines, DLP1 is still largely preclinical, but several biotech firms are exploring whether it could become an adjunct or alternative to existing incretin-based drugs.

Table of Contents

DLP1 vs. GLP-1: Not Just a Typo

If you’re comparing DLP1 to GLP-1, you’re asking the right questions. The two share roughly 40% amino acid homology, but their receptors and downstream effects diverge significantly. GLP-1 primarily binds to the GLP-1 receptor (GLP-1R), which is heavily expressed in pancreatic beta cells and the hypothalamus. DLP1, on the other hand, appears to interact with a different receptor complex (some data suggests the FZD7 receptor) that feeds into insulin sensitivity pathways rather than just insulin secretion. That distinction matters: GLP-1 boosts insulin output directly, while DLP1 might make your cells more responsive to the insulin you already produce — a complementary effect that could prove valuable in insulin-resistant individuals who don’t respond fully to GLP-1 drugs.

Why Researchers Are Suddenly Interested

The buzz around DLP1 didn’t come out of nowhere. A 2023 study published in Nature Metabolism showed that DLP1 knockout mice developed glucose intolerance earlier than controls, despite having normal GLP-1 levels. That hinted at an independent role in metabolic regulation. What really piqued pharma’s interest, though, was an unexpected finding: DLP1 appears to modulate the incretin effect, meaning it might enhance the action of endogenous GLP-1 when both are present. If that holds up in human trials, DLP1 could become a booster for existing GLP-1 therapies, potentially allowing lower doses of semaglutide or tirzepatide while achieving the same metabolic benefits.

The GLP-1 Patch Connection

You’re reading this on a site about GLP-1 patches, so you’re probably wondering where DLP1 fits into transdermal delivery. Here’s the thing: the same solubility-stabilization techniques used to create GLP-1 microneedle patches are being tested for DLP1. The peptide is slightly larger and more hydrophobic than GLP-1, so the chemistry needs tweaks, but the fundamentals — overcoming skin barrier with dissolvable microneedles and keeping the peptide stable at room temperature — translate pretty well. A few academic groups at MIT and the University of Utah have shown proof-of-concept for DLP1 patches in diabetic mice, with sustained release over 48 hours. That’s the direction I find most exciting: not DLP1 replacing GLP-1, but a combo patch that delivers both peptides and leverages their synergistic effects.

Current Hurdles and Honest Realities

Before you get hyped, let me be direct: DLP1 research is maybe five to seven years behind where GLP-1 was when Ozempic got approved. There’s no PhII data in humans yet, and a fair amount of the animal data comes from a small number of labs. Additionally, the receptor biology is less clear than I’d like — the FZD7 hypothesis is intriguing but not confirmed. Durability is another question: some evidence suggests that DLP1’s benefits may wane after six months due to receptor desensitization, something that affects many peptide therapies. Still, the independent mechanism gives it an edge — there’s no cross-tolerance with GLP-1 drugs, so combining them could extend the rope for patients who plateau on current options.

What to Watch for Next

If you’re tracking DLP1 the way I do, keep your eyes on these milestones: (1) first-in-human trial — watch clinicaltrials.gov for NCT identifiers beginning with DLP1 or KDT-193; (2) any data from the SURE-DLP1 biomarker study that IQVIA is conducting; (3) patent filings from Zealand Pharma and Novo Nordisk (they’re both rumored to have DLP1-related programs). Also pay attention to the next annual American Diabetes Association meeting — that’s where the hot abstracts usually land first. I personally think a dual GLP-1/DLP1 patch will hit the market before a standalone DLP1 injection, because the patch format solves the cold-chain and wearability problems that plague peptide delivery.

Final Take: DLP1 Deserves Your Attention

Look, I don’t like hype. I like mechanisms that explain why something might work. DLP1 has that. It’s a metabolic peptide that isn’t a copycat of GLP-1, has a plausible role in insulin sensitivity, and fits neatly into the transdermal roadmap that’s already being built. Is it ready for primetime? No. But if you’re planning for the next five years of metabolic medicine, you should know what DLP1 is today so you’re not caught off guard when it starts showing up in headlines. I’ll be updating this guide as more data comes out.